About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Prevalence of BRCA in Patients With Ovarian Cancer

NCT02222883·20 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AGO Research GmbH

Explorative analysis will be performed.

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Female ovarian cancer patients aged \>= 18 years.
Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer.
Multiple platinum based prior therapies are allowed.

You may not be if

Non-epithelial ovarian malignancy.
Platinum-resistant or refractory disease.
Paraffin embedded tumor samples not available.

The record

StatusCompleted

PhaseNo phase

Taking part530

StartedMar 2015

UpdatedJun 16, 2021

Conditions

BRCA Status Ovarian Cancer

Where20

Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinik Carl Gustav Carus
Dresden, Germany
Evangelisches Krankenhaus
Düsseldorf, Germany

Clareo Health | Prevalence of BRCA in Patients With Ovarian Cancer